Jane Street’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-31,608
| Closed | -$509K | – | 12308 |
|
|
2025
Q4 | $510K | Sell |
31,608
-5,055
| -14% | -$66.9K | ﹤0.01% | 7642 |
|
|
2025
Q3 | $447K | Sell |
36,663
-18,247
| -33% | -$252K | ﹤0.01% | 8099 |
|
|
2025
Q2 | $621K | Buy |
+54,910
| New | +$671K | ﹤0.01% | 6526 |
|
|
2025
Q1 | – | Sell |
-69,397
| Closed | -$708K | – | 10049 |
|
|
2024
Q4 | $588K | Buy |
69,397
+48,889
| +238% | +$506K | ﹤0.01% | 6437 |
|
|
2024
Q3 | $237K | Sell |
20,508
-16,505
| -45% | -$208K | ﹤0.01% | 8395 |
|
|
2024
Q2 | $436K | Sell |
37,013
-307,436
| -89% | -$3.59M | ﹤0.01% | 7236 |
|
|
2024
Q1 | $4.09M | Buy |
344,449
+306,932
| +818% | +$4.09M | ﹤0.01% | 2936 |
|
|
2023
Q4 | $460K | Buy |
37,517
+4,833
| +15% | +$44K | ﹤0.01% | 6902 |
|
|
2023
Q3 | $315K | Buy |
+32,684
| New | +$334K | ﹤0.01% | 6993 |
|
|
2023
Q1 | – | Sell |
-15,498
| Closed | -$105K | – | 9478 |
|
|
2022
Q4 | $105K | Buy |
+15,498
| New | +$83K | ﹤0.01% | 8062 |
|
|
2021
Q4 | – | Sell |
-19,797
| Closed | -$345K | – | 10473 |
|
|
2021
Q3 | $345K | Buy |
19,797
+7,618
| +63% | +$154K | ﹤0.01% | 7924 |
|
|
2021
Q2 | $292K | Buy |
+12,179
| New | +$319K | ﹤0.01% | 8186 |
|
Other funds holding KALV
Jane Street's KALV Position: Q1 2026 in Review
Jane Street sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 31,608 shares — an estimated $509K sold.
Jane Street first reported a position in KALV in Q2 2021 and held it in 12 quarters. The position peaked at $4.09M in Q1 2024. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.
- Jane Street reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Jane Street sold 31,608 KalVista Pharmaceuticals shares in Q1 2026, an estimated $509K.
- Jane Street first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 12 quarters.
- Jane Street's KalVista Pharmaceuticals position peaked at $4.09M in Q1 2024.
- 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.